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Abstract 
 
During ISS and shuttle missions, difficulties with sleep affect more than half of all US crews.  
Mitigation strategies to help astronauts cope with the challenges of disrupted sleep patterns can 
negatively impact both mission planning and vehicle design. The methods for addressing known 
detrimental impacts for some mission scenarios may have a substantial impact on vehicle 
specific consumable mass or volume or on the mission timeline.  As part of the Integrated 
Medical Model (IMM) task, NASA Glenn Research Center is leading the development of a 
Monte Carlo based forecasting tool designed to determine the consumables required to address 
risks related to sleep disruption.  The model currently focuses on the International Space Station 
and uses an algorithm that assembles representative mission schedules and feeds this into a well 
validated model that predicts relative levels of performance, and need for sleep (SAFTE Model, 
IBR Inc).  Correlation of the resulting output to self-diagnosed needs for hypnotics, stimulants, 
and other pharmaceutical countermeasures, allows prediction of pharmaceutical use and the 
uncertainty of the specified prediction.  This paper outlines a conceptual model for determining a 
rate of pharmaceutical utilization that can be used in the IMM model for comparison and 
optimization of mitigation methods with respect to all other significant medical needs and 
interventions.  
 
https://ntrs.nasa.gov/search.jsp?R=20090005021 2019-08-30T06:00:56+00:00Z
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INTRODUCTION 
Maintaining high alertness and 
performance levels during space operations 
is critical to both the safety and success of 
the mission.  However, research has shown 
that performance decrements occur during 
spaceflight and it is not uncommon for these 
observed decrements to be associated with 
reductions in sleep quality and quantity 1-3. 
Subjective and objective  measures have 
shown that daily sleep duration during orbit 
is around 6 hours and can even be as few as 
4 hours per day 3-8.  This quantity of sleep is 
significantly less than the average daily 
sleep need of ~ 8 hours considered 
necessary to maintain alertness and 
performance across waking hours. Sleep loss 
continues to be documented across in-flight 
days with total durations being even further 
reduced prior to mission critical tasks 9. 
Figure 1 illustrates a typical sleep situation 
on board the US Space Shuttle in which it is 
clear that environmental factors including 
confined space and lack of a secure sleeping 
quarters (i.e., sharing sleeping space with 
others) can also contribute to reduction in 
the quality of sleep in space. 
The challenge of crew members 
obtaining consolidated and efficient sleep, 
i.e. uninterrupted and restorative sleep, is 
further evidenced by the increasing reports 
of the use of sleep aids and hypnotics during 
flight. While less than 50% of astronauts 
requested or reported using sleep medication 
during a shuttle mission in the mid 1990’s 10, 
11
, recent subjective data collected for 10 US 
Space Shuttle flights have shown that 81% 
of crew members reported using medication 
to help them sleep 9. The data also revealed 
that astronauts reported using sleep aids 
during 50% of in-flight days and not just 
during the first few days in orbit, which is 
considered to be an adjustment period.  
Although the majority of sleep/wake 
data and the prevalence of sleep aid and 
hypnotic use have been collected during 
shuttle operations, the same factors that 
challenge human physiology remain. These 
factors include, but are not limited to, 
insomnia, disrupted sleep schedules due to 
operations scheduled for off-nominal hours, 
noise levels within the spacecraft, 
physiological adaptation to microgravity, 
and the need to, and complications with, 
voiding. 
 
 
Figure 1. Pam Melroy, George Zamka, bottom 
right,and European Space Agency's Paolo Nespoli, 
sleep in the of the Space Shuttle Discovery 
middeck while docked with the International 
Space Station, Thursday, Nov. 1, 2007.  
(http://www.daylife.com/photo/05m194q0hQcNl, 
original provided by NASA) 
 
Given the risks associated with sleep 
loss during space flight, NASA continues to 
focus research on the development of 
countermeasure and intervention approaches 
that will optimize sleep/wake cycles during 
flight.  Mitigation strategies have been 
implemented, including those that require 
pharmacological consumables, to avoid 
increased operational risks associated with 
chronic sleep loss.  However, There is a 
need to predict, based on what already 
occurs during space flight, the level of sleep 
disruption and sleep loss expected for future 
missions so that related factions influencing 
mission planning and consumable usage can 
be better understood.. 
The Sleep Disruption-Medical 
Intervention Forecasting (SDMIF) tool is 
being developed to estimate the occurrence 
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and severity of sleep loss. This tool will 
assist International Space Station (ISS) 
planners in identifying the optimal amount 
of sleep promoting and alertness enhancing 
pharmaceuticals needed to ensure astronaut 
performance during all future space flight 
operations through its integration into the 
Integrated Medical Model (IMM). 
IMM and SDMIF 
As part of the NASA Exploration 
Medicine Capability Project, the IMM is 
being developed to help guide exploration 
planning, requirements development, and 
R&D investment activities.  The IMM is a 
software-based system that will identify and 
quantify the medical needs and health risks 
of exploration crew members during space 
flight, as well as evaluate potential 
mitigation strategies.  The IMM project 
employs an evidence-based approach to 
quantify probable consequences of all 
potential in-flight medical events for 
different space mission scenarios.  The 
approach incorporates success probabilities 
of typical treatment strategies to respond to 
each medical event and those of pre-flight 
and in-flight efforts to address maintaining 
crew health in order to avoid the medical 
event occurrence.   
The IMM uses Monte Carlo 
simulations and other stochastic techniques 
to simulate planned mission scenarios and 
quantify levels of medical risk by utilizing 
the best available evidence and 
understanding with regard to the occurrence 
and successful response to medical 
conditions in space.  These quantified 
scenarios will ultimately inform decision 
makers of the relative impact of potential 
medical risks and enable objective 
assessment of crew health and optimization 
of mission success. For more information 
regarding the development of the IMM 
Project see Fitts et al.12. 
The goal of the NASA – Glenn 
Research Center Sleep Disruption-Medical 
Intervention Forecasting (SDMIF) tool is to 
assist planners using the IMM to optimize 
the medical supplies (i.e. consumable 
pharmaceuticals) required to treat sleep 
related challenges in order to ensure mission 
success and astronaut performance.  Similar 
modeling processes have been developed at 
the NASA-Glenn Research Center to 
estimate the likelihood of bone fracture for 
planning and optimization of various space 
missions 13, 14.  The following paragraphs 
describe the SDMIF conceptual model 
structure and the planned implementation, 
illustrate preliminary results, and discuss 
remaining efforts, as well as model 
application and known limitations of the 
approach. 
MODEL OUTLINE 
The IMM model uses the SDMIF 
tool to obtain an estimate of the amount of 
stimulant, hypnotic medication, and other 
pharmaceutical countermeasures that are 
needed during space flight missions, based 
on the current state of knowledge of sleep 
conditions and operational planning. To 
accomplish this goal, the SDMIF tool 
addresses the disruption of normal sleep 
patterns associated with mission operations 
and environmental conditions by integrating 
an industry accepted sleep performance 
model and research data regarding the use of 
sleep aids.  
Model Requirements 
To address the needs of the IMM 
parent tool and to simplify the integration 
effort, the SDMIF is designed to meet 
several requirements.  The primary 
requirement is that the SDMIF tool has the 
ability to predict the incidence rate and 
probability of a clinically significant 
occurrence of circadian rhythm disruption, 
insomnia, sleep deprivation or other 
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significant sleep disturbance.  In this case, a 
clinically significant occurrence is defined 
as a condition that would be recognized by a 
physician medical operations officer 
(clinical diagnosis) or the impaired crew 
member (self diagnosis) resulting in some 
level of intervention.  In most cases this 
would be modeled as a need to use a 
hypnotic to promote consolidated and 
efficient sleep during prescribed sleep 
periods or to use a stimulant during work 
periods to help maintain performance levels.  
To be used as a planning tool within the 
IMM, the rate of use is to be provided in the 
form of a probability density function, 
which describes the most likely rate of 
consumption per astronaut per mission time 
in addition to the uncertainty in the estimate. 
Further requirements of the SDMIF 
tool focus on insuring that appropriate 
consideration is given to the underlying 
causes resulting in the need for medical 
intervention.  Generally, this means that the 
predicted schedule, means of diagnosis, and 
forecasted rate of intervention is in 
agreement with the past experiences of 
mission crews and medical operations 
personnel.  The desired outcome is that 
factors that affect sleep quantity and quality 
are adequately assessed such that simulated 
sleep/wake periods are indistinguishable 
from those observed in past missions given 
the same initial parameters and planned 
schedule.  Similarly, the means of diagnosis, 
such as sleep drive, performance decrement, 
or operational standards, must be 
appropriate for the specified scenario in 
order to adequately forecast the rate of 
medical intervention. 
Initial development of the model is 
to focus on the sleep/wake patterns for 
Shuttle and ISS crew due to the abundance 
of information available from experience on 
these vehicles. This will help future ISS 
increments more adequately plan their 
pharmaceutical stores.  Further, successful 
implementation focused on ISS missions 
will provide a baseline, from which 
adjustments can be made for use in more 
complex mission scenarios, such as to the 
moon and Mars. 
Conceptual Model 
Figure 2 graphically outlines the 
conceptual framework for the SDMIF 
modeling tool, which includes four major 
components: a mission parameter module, a 
well validated sleep and performance model, 
a sleep drive metrics translation function, 
and a diagnostic decision making tool.  
 
 Mission parameters 
(Timelines of activity and 
sleep amounts over the mission)
Sleep and performance 
(Calculation of sleep and 
performance metrics)
Metrics
(Conversion of sleep metrics to 
diagnosis metrics)
Diagnosis
(Comparison of metrics to 
thresholds)
Probability 
(Conversion of number of 
diagnoses to rate at which 
medication is prescribed)
Monte Carlo 
simulations 
performed 
on these modules
 
Figure 2. Conceptual Outline of Modeling 
Tool Structure  
 
In concept, the model algorithm 
assembles representative mission sleep 
opportunities and actual sleep times and 
predicts human effectiveness levels based on 
these patterns.  This information is 
transformed into metrics representative of 
measures for the need for sleep, compared to 
threshold values to diagnose the likelihood 
for treatment.  The metrics are correlated to 
the likelihood that a consumable mitigation 
approach is used during a particular mission 
day.  The components of the model are 
integrated within a Monte Carlo simulation 
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to provide a predicted rate of consumables 
that corresponds to the wide variations in 
affecting parameters over the course of an 
entire mission.   
Model Components  
Overview 
As described in the Conceptual 
Model section, a Monte Carlo approach is 
taken to address the wide variation within 
the parameters contributing to the 
occurrence of sleep disruption and for 
forecasting the need for medical 
intervention.  Relative to the statistical 
variation of the input parameters, the Monte 
Carlo simulation randomly samples each 
parameter space as required by each module.  
Each trial of the model then consists of a 
random combination of the model 
parameters that represents a reasonable 
scenario based on the available data.  The 
results are integrated over the random trials 
of the mission scenario to prescribe the rate 
at which medical intervention is required 
due to sleep disruption.  Convergence of the 
simulation is said to be achieved when the 
standard deviation of the output PDF varies 
by less than 0.01 for each additional 100 
sample trials.  By encapsulating these 
modules in this manner, a statistically 
relevant representation of the rate of 
consumable use, an understanding of the 
uncertainty in the estimate and information 
of the chief contributors to that uncertainty 
are developed.   
Mission parameter module 
The mission parameter module 
generates realistic ISS mission schedules of 
sleep and wake times. The schedules include 
events that cause a shift in the sleep 
schedule, the best available data on the 
actual amount of sleep obtained by 
astronauts in space and the quality of that 
sleep. The program takes into account the 
uncertainty in these parameters by using 
distributions rather than single values for the 
parameters. During each trial1 of the Monte 
Carlo simulation a new schedule is 
generated from the parameter distributions. 
The output of the mission parameter 
program is a matrix where each row 
represents a mission day and each column 
represents a one minute time increment 
throughout the day, from 00:00 to 23:59. 
The matrix is filled with ones and zeros. A 
one indicates the astronaut is awake during 
that time increment and a zero indicates the 
astronaut is asleep.  
Astronauts are scheduled to be 
awake from 06:00 to 21:30 GMT during a 
normal International Space Station (ISS) 
mission day. ISS extra-vehicular activities 
(EVAs) and Shuttle, Soyuz and Progress 
dockings are critical events that require a 
shift in the work day. The mission parameter 
program incorporates a representative 
number of these events, based on historic 
data, and shifts the scheduled work day 
accordingly. The normal scheduled sleep 
opportunity for astronauts is 8.5 hours per 
night and studies have quantified the actual 
amount of sleep obtained during that sleep 
opportunity 3, 15. A distribution for the actual 
amount of sleep obtained per night was 
developed for our model from these reported 
data 3, 15. 
The quality of sleep depends upon 
the frequency and quantity of wakefulness, 
or interruptions, during a sleep period. 
Modeling occurrences and types of 
interruptions within the sleep periods was 
based on measured sleep pattern data from 
past US space missions 3, 16. 
The mission parameter information 
is converted into input compatible with sleep 
and performance module.  Transitions 
between work and sleep are determined by 
                                                 
1
 A trial is defined as one pass through the SDMIF, 
representing a single mission simulation, with one set 
of randomly determined parameters   
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calculating the difference between adjacent 
matrix elements across all days of the 
simulated mission. Three possible cases 
exist: the difference equals negative one, 
representing a wake event (0-1), positive 
one for a sleep event (1-0), and zero for no 
change (0-0 and 1-1). After all transitions 
are located, the time and duration of 
work/sleep periods are calculated. This 
information, along with initial conditions 
and other variables related to the quality of 
sleep during sleep periods are converted into 
an XML file for input into the sleep and 
performance module. 
Sleep and performance module: 
SAFTE 
The effects of sleep timing and 
duration and the influence of time of day 
(circadian effects) on performance are 
estimated using the Sleep, Activity, Fatigue, 
and Task Effectiveness (SAFTE) Model, 
(IBR Inc) model.  This model was chosen 
for five reasons:  
1. it predicts performance in non-
arbitrary units of performance 
effectiveness that relate directly to 
performance on a psychomotor 
vigilance task. 
2. it requires a minimum number of 
input variables. 
3. it has a method for reflecting the 
degrading effects of sleep 
fragmentation or sleep interruptions. 
4. it tracks changes in circadian phase 
based on changes in the work/rest 
schedule that commonly occur on 
ISS. 
5. it has been validated as an accurate 
predictor of risk in the work 
environment17. 
At the center of the model is a sleep 
reservoir which, along with the circadian 
rhythm and sleep inertia, determines 
performance effectiveness.  Each unit of the 
reservoir is equal to 1 unit of effectiveness 
that is accumulated during normal sleep at 
the average rate of 1 unit per minute and 
used during time awake at the rate of 0.5 
units per minute.  Hence, 8 hours of sleep 
provides enough units of effectiveness to 
sustain 16 hours of performance.  The 
capacity of the reservoir is sufficient to 
sustain continuous performance for a 
maximum of 96 hours, or 2880 units.  The 
reservoir percent fill is defined as the linear 
component of percent effectiveness function 
while awake.  The reservoir component 
sums with a circadian oscillator (a two 
component cosine function) which is 
defined in +/- units of percent effectiveness, 
and with a sleep inertia function, defined in 
units of temporary deficit in percent 
effectiveness immediately following 
awakening.  The SAFTE model will directly 
predict changes in percent effectiveness 
within the practical range of zero sleep 
deprivation (nominal 8 hours of sleep per 
day) to 96 hours of continuous sleep 
deprivation2.  Actual data may be compared 
to the model by plotting the performance as 
percent of baseline; baseline being defined 
as the average performance of a person fully 
rested and fully trained on the task being 
tested.   
During periods of scheduled sleep, 
the model replenishes the sleep reservoir.  
The rate of accumulation or sleep intensity 
is determined by the amount of deficit in the 
reservoir and the circadian drive to sleep 
based on time of day.  Further, the SAFTE 
model incorporates simple logic to reflect 
the degradation of sleep benefits caused by 
interruptions in sleep in unfavorable 
sleeping environments or when a crew 
member is suffering some from of 
discomfort. 
The SAFTE model has been 
validated against laboratory data on sleep 
restriction and a major study of railroad 
                                                 
2
 Note: the maximum duration of sleep deprivation in 
the literature is less than 85 hours.   
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accidents has demonstrated that the model 
can predict increases in accident likelihood 
and severity (risk) based entirely on work 
schedule data 17. 
For this project, each trial wake/sleep 
schedule generated from the Monte Carlo 
sampling is passed through the SAFTE 
model to determine both the predicted levels 
of performance effectiveness and predicted 
levels of sleep intensity while scheduled to 
be asleep over the mission duration.  
Difficulties sleeping will be inferred from 
the co-occurrence of a scheduled period of 
sleep and a low level of predicted sleep 
intensity.   
Diagnosis module 
The diagnostic module remains 
under construction, but the conceptual 
framework has been generated.  In general 
the diagnosis module is a means of relating a 
prospective need for sleep to the likelihood 
that a sleep aid is utilized to achieve 
restorative sleep.  The underlying premise of 
this approach is that below a certain 
threshold of estimated sleep intensity, a 
pharmaceutical intervention is likely to be 
utilized. The specification of this threshold 
level will likely be complex, with inter-
individual differences contributing to a wide 
uncertainty in exact specification.  
To account for the expected 
uncertainty and to forecast the use of a sleep 
aid during a sleep period within the mission, 
a two step process is followed: 
1. Calculate the probability a sleep aid 
is needed and used.  This is termed 
the Probability of intervention. 
2. Execute a decision process to decide 
if a sleep aid is used for that sleep 
period. 
The forecasted utilization for pharmaceutical 
sleep aids is summed over each trial mission 
and a rate per unit day per astronaut is 
determined.  The probability density 
function (PDF) output of the Monte Carlo 
simulation is then generated from the 
ensemble average of the forecasted rates of 
usage. 
Estimating the probability of a 
pharmaceutical intervention based on 
assessments of sleep intensity and other 
sleep metrics could be accomplished with a 
sigmoid function as illustrated in Figure 3.  
The sigmoid formulation provides a feasible 
translation function that can be derived from 
estimates of the sleep metric (intensity) 
threshold (taken to be the point where an 
intervention is more likely than not, i.e. Pr > 
50%).  Uncertainty in the actual 
interventional threshold can be represented 
as a family of probability mapping 
functions, whose parameters can be 
specified as functions within the Monte 
Carlo Simulation.  Efforts to specify this 
formulation are ongoing.   
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Figure 3.  Illustration of type and form of the 
transfer function that will relate sleep intensity to 
probability of interventional medication.  The 
data points at 0 and 1 illustrate how the non –use 
or use of a sleep aid will be combined with 
estimated % sleep intensity predicted by SAFTE 
to estimate the probability of intervention to 
promote sleep. 
 
The decision process for determining 
the predicted use of a sleep aid during a 
sleep period utilizes probability of 
intervention and the fact the parent model is 
executing a Monte Carlo trial.  To 
accomplish the decision making step, the 
probability of intervention is assumed to be 
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a YES-NO (special case binomial 
distribution), which can be sampled in the 
same manner as the parameter values within 
the overall Monte Carlo simulation.  In 
effect this removes the necessity to simulate 
subjective perception of sleep difficulty 
from the decision making process of a 
particular instance and replaces it with a 
random sampling of the statistical likelihood 
of the sleep aid usage.   
DISCUSSION  
A numerical approach has been 
developed to generate quantitative estimates 
of the utilization of sleep aids on space 
missions.  As part of the IMM project, the 
SDMIF tool concept outlines probabilistic 
and stochastic modeling techniques, in 
conjunction with validated models of sleep 
and performance, to forecast the need for 
medical intervention throughout a specified 
mission scenario.  With this approach, the 
SDMIF will enable informed mission 
planning and allow for relative comparison 
of benefits and determents of adverse health 
mitigation strategies with respect to all 
medical events simulated in the IMM frame 
work.  At present the model is designed to 
address only the forecast of the utilization of 
sleep aids, but will be extended to address 
interventional medications that address other 
sleep and fatigue issues related to 
performance. 
The SDMIF framework is structured 
similar to an object oriented program, where 
encapsulated sections of data and model 
processes can be replaced as new data or 
more appropriate processes are developed.  
At the core of the SMDIF is the use of a 
well validated sleep and fatigue model.  In 
the SDMIF developmental framework, 
SAFTE was chosen due to its comparative 
versatility to other models and will be used 
as a bench mark with the overall model 
structure.  Compared to other fatigue 
models, the SAFTE model has many fewer 
estimation parameters required to predict 
performance and minimal input 
requirements to represent the effects of a 
given schedule.  SAFTE also includes 
components that permit the model to 
represent the performance and sleep 
disruptions associated with sudden shifts in 
schedule and the rate of adaptation to such 
disruptions.  However, other models are in 
development that could provide additional 
insight into space mission sleep 
interventions18.  Due to the versatile 
framework of the SDMIF structure, it will 
be possible to incorporate other 
sleep/performance models as needed in 
future versions. 
Preliminary work with the SAFTE 
model to illustrate the expected changes in 
sleep intensity between generic terrestrial 
works days and generic ISS work days is 
shown in figure 4.  Comparison of the daily 
output values illustrates that at a predicted 
sleep intensity of 0.55, initiation of sleep 
would likely be difficult.   
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Figure 4.  SAFTE output for a generic terrestrial 
work day. At times when sleep intensity is less 
than 0.55 units, it is proposed that SLEEP 
INITIATION would be difficult, a request for a 
sleep aid would be more likely (i.e. the probability 
is greater than 50%) and that the degree of risk 
would be inversely proportional to sleep intensity 
below 0.55.  
 
Work continues to complete the SMDIF 
metric conversion and diagnosis modules 
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with expected completion and validation by 
the end of Calendar year 2009 at which 
point an internal review with subject matter 
experts from NASA and supporting 
organizations will be conducted.  After a 
successful review the SDMIF output will be 
integrated into the IMM parent model.   
Limitations 
Probabilistic models are inherently 
difficult to validate, especially for space 
mission scenarios where much of the data 
normally used in validation must be 
included in the model.  When possible, the 
predicted rate of use of sleep-decrement 
associated consumables will be compared to 
reference mission data from existing ISS 
increments for validation.  However, this is 
expected to provide limited validation until 
further studies isolating the per astronaut 
utilization of medications are completed.  In 
the mean time, an advisory board with 
members from the space life science 
community, specializing in Space flight and 
the impact of sleep disruption and inhibition 
will provide guidance and a “face-
validation” to the model concept, data 
utilized, and model implementation. 
As indicated in the text, the 
versatility of the SAFTE model provided 
sufficient cause for its use in the 
development stage of the SDMIF, it does not 
preclude the use of other modeling schemes 
developed to have more focused application 
to addressing to the rigors of space flight on 
sleep18.  As the SDMIF frame work is 
straightforward, it should be straightforward 
to integrate these more specific models if 
deemed necessary.   
Although the SDMIF tool is based 
on probabilistic risk analysis and stochastic 
modeling techniques, the primary goal is not 
to predict risk of a given performance 
decrement or how such a decrement could 
impact a mission outside the predicted rate 
of consumable use.  The model is currently 
specific to IMM requirements and does not 
directly address NASA Human Research 
Program gaps associated with sleep and 
human performance. However it may be 
modified to address such gaps in the future, 
as well as, provide a foundation to address 
these gaps. 
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Abstract 
 
During ISS and shuttle missions, difficulties with sleep affect more than half of all US crews.  
Mitigation strategies to help astronauts cope with the challenges of disrupted sleep patterns can 
negatively impact both mission planning and vehicle design. The methods for addressing known 
detrimental impacts for some mission scenarios may have a substantial impact on vehicle 
specific consumable mass or volume or on the mission timeline.  As part of the Integrated 
Medical Model (IMM) task, NASA Glenn Research Center is leading the development of a 
Monte Carlo based forecasting tool designed to determine the consumables required to address 
risks related to sleep disruption.  The model currently focuses on the International Space Station 
and uses an algorithm that assembles representative mission schedules and feeds this into a well 
validated model that predicts relative levels of performance, and need for sleep (SAFTE Model, 
IBR Inc).  Correlation of the resulting output to self-diagnosed needs for hypnotics, stimulants, 
and other pharmaceutical countermeasures, allows prediction of pharmaceutical use and the 
uncertainty of the specified prediction.  This paper outlines a conceptual model for determining a 
rate of pharmaceutical utilization that can be used in the IMM model for comparison and 
optimization of mitigation methods with respect to all other significant medical needs and 
interventions.  
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Topics to cover
• Overview
– Integrated medical model (IMM)
– Need for determining the rate and total sleep intervention medication
• Sleep disruption-medical intervention forecasting (SDMIF) tool
– Conceptual model structure
– Model assumptions
– Model output
• Model components and supporting data
– Forecasting mission parameters
– Estimating sleep and performance measures
– Diagnosis the need for medications
• Sample calculations and model uncertainty
• Validations of the model
• Conclusions 
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Integrated Medical Model (IMM)
• Captures and uses organizational knowledge across the space medicine, 
systems engineering, logistics, and research domains.  
• Uses this domain knowledge in the context of mission constraints and profiles, 
crew profiles, and in-flight medical capabilities to forecast impacts to the 
mission due to medical events.
• Identify medical resources necessary to optimize health and mission success.
Likelihood of occurrence, 
probable severity of 
occurrence, and 
optimization of treatment 
and resources.
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Space Flight and Sleep
• Space flight induces reductions in 
sleep quality and quantity 
– Potential performance decrements 
• Primary mitigation
– Consolidated and efficient sleep
• Power naps
• Extended sleep opportunities
• Impacted by scheduling and 
environmental factors
– Medications or sleep aids
• Medication usage rates not explicitly 
known
• Challenge in support of the IMM:
– Develop a tool to estimate rates of 
medical intervention resulting from 
low sleep quality and duration
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Sleep Disruption- Medical Intervention Forecasting 
(SDMIF) Tool
• Model requirements
– Predict the incidence rate of clinically 
significant sleep disturbance
• Circadian rhythm disruption, insomnia, 
environmental disruptions
– Predicted schedule, means of 
diagnosis, and forecasted rate of 
intervention is in agreement with the 
past experiences
• Conceptual model structure
• Underlying assumptions
– Utilize validated modeling of sleep and 
performance
– Sufficient data exists to allow 
statistically representation of events
Mission
Parameters
Sleep &
Performance
Diagnosis
& Decision
Probabilities
& Rates
Metrics
Translation
Monte Carlo Simulation
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Mission Parameter Component
• The mission parameter component generates 
realistic ISS mission schedules of sleep and wake 
times. 
• The key components of the mission parameter 
module are: 
– Sleep/wake schedule, including shifting
– Actual sleep time within a scheduled sleep period
– The sleep quality of the actual sleep
• The program takes into account the uncertainty in 
these parameters by using distributions rather than 
single values for the parameters.
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Mission Parameter Component
Sleep/wake schedule
• During a normal day on ISS the astronaut is awake 
from 6:00 – 21:30 GMT, and their sleep opportunity is 
from 21:30 – 6:00 GMT.
• Critical operations include:
– EVAs
– Unmanned dockings (i.e. Progress)
– Manned dockings at the end of an increment (Shuttle and 
Soyuz)
• Many of the critical operations include shifts to the 
sleep/wake schedule including:
– Slam shifts and gradual shifts
– Phase advance and phase delay shifts
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Mission Parameter Component
Sleep/wake schedule
• The output of the mission parameter component is a matrix of 1’s and 
0’s. A 1 indicates the astronaut is awake, a 0 indicates the astronaut is 
asleep. The matrix is graphically shown here with a * representing a 1. 
References:
1) Personal communication 
with Lauren Leveton  
2008.
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Mission Parameter Component
Actual sleep
• A relationship exists between time in space and the 
number of hours of sleep per night obtained. 
• Data from shuttle and Skylab missions were used to 
quantify the relationship.
References:
1) Dijk DJ, Neri DF, Wyatt JK et al. Sleep, 
performance, circadian rhythms, and 
light-dark cycles during two space 
shuttle flights. Am J Physiol Regul
Integr Comp Physiol 2001; 
281(5):R1647-R1664.
2) Frost JD, Shumate WH, Salamy JG, 
Booher CR. Experiment M133. Sleep 
monitoring on Skylab. In: Johnston RS, 
Dietlein LF, editors. Biomedical Results 
from Skylab. Washington, DC: NASA; 
1997.
3) Personal Communication with Laura 
Barger.  2008.
918.50129.0 += xy
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Mission Parameter Component
Sleep quality
• The quality of sleep depends upon the frequency and 
quantity of wakefulness, or interruptions, during a 
sleep period
• A sleep factor correlated to sleep quality uniformly 
distributes sleep loss due to interruptions throughout 
the sleep period 
References:
1) Dijk DJ, Neri DF, Wyatt JK et al. Sleep, performance, circadian rhythms, and light-dark cycles 
during two space shuttle flights. Am J Physiol Regul Integr Comp Physiol 2001; 
281(5):R1647-R1664.
2) Personnal Communication with Laura Barger.  2008.
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Sleep and Performance Component
• Use an accepted sleep model to determine the effects of sleep timing and 
duration and the influence of time of day (circadian effects)
• SAFTE proprietary process 
– Allows the tracking of changes in circadian phase based on changes in the work/rest 
schedule such as those that commonly occur on ISS
– Accurately reflects the degrading effects of sleep fragmentation or sleep interruptions
• SAFTE input
– Mission Schedule and Astronaut parameters
1
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Sleep and Performance Component
SAFTE Output
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0.55, threshold limit 
below which sleep 
initiation becomes 
difficult
Sleep initiation difficult in 
this region, increased 
probability of sleep aid.
Recovery sleep intensity following night 
of poor sleep and extra long work day.
Typical pattern of sleep intensity 
following normal work period, 
mean intensity = 1 unit per minute.
• Measures of
– Effectiveness
– Sleep 
Reservoir
– Sleep 
intensity
• Diagnostic 
Metric
– Sleep 
intensity is a 
measure of 
the relative 
circadian 
process and 
the level of 
sleep debt
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Diagnosis and Decision Component
• Must answer
– At what “threshold level” of sleep 
intensity does intervention occur 
• Approach
– Associate sleep intensity with 
probability that medication is 
used
– Logistic regression of ground and 
space based data
• Output is a probability of using a 
sleep aid
– Relative to each scheduled sleep 
period
• Decision of sleep aid use is 
based on binomial representation 
of this probability estimate
• Component still under 
development
– Currently integrating new data
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Illustration of How Model will Trigger 
Increased Probability of Sleep Aide Use
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Probability and Rates Component
• Calculations through an entire mission set is a trial within 
the Monte Carlo Simulation
– Represents a possible mission based on the input parameters
– Many simulations with random (but realistic) parameters 
produces 
• The most probable rate of medication uses
• The associated uncertainty in the rate of usage estimate
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Validation
• Hard to validate probabilistic 
models
– Typically Face validation with SME
• Validation individual components
– Sample schedules generated from 
the mission parameter program will 
be given to mission schedulers for 
evaluation of how well they 
represent ISS mission schedules
• Validation of model conceptual 
structure 
– SME review and advisory panels
• Comparison and Refinement 
based on ongoing work
– In flight sleep data
– Ground based studies
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Ongoing Efforts and Limitations
• Completing V1.0 by 2009  
• The diagnosis probability translation function is likely not a 
single curve
– More likely a family of curves whose variation represents individual 
variation not accounted for in the model
– Currently examining this issue
• SAFTE not originally designed for non-terrestrial usage
– Modifications being made to address this issue
– Modular nature of the modeling approach allows other sleep 
analysis simulations to be used if needed
• SDMIF tool is not currently designed to predict a given 
performance decrement
– Specifically structured to implement in the IMM
– Outlining how approach will be augmented to address sleep 
induced performance risk for the NASA HRP-BHP
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SAFTE
• The Sleep, Activity, Fatigue, and Task Effectiveness 
(SAFTE) Model is based on 12 years of fatigue modeling 
experience and over $3M of US DOD investment.
• Validated against laboratory and simulator measures of 
fatigue. 
• Validated and calibrated to predict accident risk by the 
Department of Transportation.
• Peer reviewed and found to have the least error of any 
available fatigue model.
• Now accepted by the US DOD (Air Force, Army, 
Navy, Marines) as the common warfighter fatigue 
model.
21www.nasa.gov
Sleep and Performance Component
SAFTE Output
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